Artificial Intelligence · Profile from AI Research Companion

InstaDeep

The AI company that Karim Beguir and Zohra Slim started in Tunis in 2014 with two laptops and about $2,000 (as the founders tell it), which moved its headquarters to London in 2015, sold "decision-making AI" (optimisation and reinforcement learning) to railways, logistics firms and chip designers, and became Africa's best-known AI exit when BioNTech bought it in 2023 for up to ~£562m (~£362m up front in cash and shares plus up to ~£200m of milestones; company). Inside BioNTech it is two businesses at once: an in-house AI lab for mRNA vaccines and cancer immunotherapy (variant early warning, neoantigen and antibody design, the Nucleotide Transformer genomics models, the Kyber GPU cluster), and a commercial unit that still sells optimisation software to industry (DeepPCB, Deutsche Bahn, Wilo). It is not a model lab in the OpenAI sense. Its importance in this knowledge base is as a case of how an emerging-market AI company reached a global exit by selling to global customers, and of what happens to an acquired AI team when the acquirer's own business shrinks (section 24).

At a glance

Founded: 2014, Tunis, Tunisia, by Karim Beguir (CEO) and Zohra Slim (co-founder); headquarters moved to London in 2015
Headquarters: London; offices in Paris, Tunis, Kigali (opened October 2023), Cape Town, Mainz (with BioNTech) and the US; earlier offices reported in Lagos, Berlin and Dubai (verify current list)
Ownership / structure: Wholly owned UK subsidiary of BioNTech SE (Nasdaq: BNTX) since 2023; BioNTech held ~5.3% before the deal and bought the other ~94.7% (company)
Leadership (2026): Karim Beguir (co-founder and CEO); Zohra Slim (co-founder; verify current title); reports into BioNTech, whose co-founders Uğur Şahin and Özlem Türeci announced on 10 March 2026 that they would step down by the end of 2026; Guido Oelkers named BioNTech CEO on 3 August 2026, to take over by 1 February 2027 at the latest (reported)
AI products: DeepPCB (AI circuit-board placement and routing, 2019; DeepPCB Pro with Google Cloud, September 2024); decision-making and scheduling systems for Deutsche Bahn, Fraport and others; Nucleotide Transformer DNA models (2023; NTv3 preprint December 2025); AgroNT (crop genomics); Bayesian Flow Network protein models (ProtBFN, AbBFN2); InstaNovo (peptide identification from mass spectra); Laila lab assistant (2024, built on Meta's Llama 3.1); DeepChain platform; AIchor (internal ML-operations platform); InstaGeo (open geospatial framework)
Scale: ~240 staff at the January 2023 announcement, ~290 transferred at closing, >400 at end-2024 (reported); revenue £34.4m (2023) and £61m (2024), per UK accounts filed August 2025 (reported); operating loss ~38% of revenue (2023) and ~3% (2024) (reported); Kyber cluster of 224 Nvidia H100 GPUs (October 2024, company)
Capital raised: ~$7m Series A led by AfricInvest (2019, reported); $100m Series B co-led by Alpha Intelligence Capital and CDIB Capital, with BioNTech, Google, G42, Chimera Abu Dhabi, Deutsche Bahn's DB Digital Ventures and Synergie (25 January 2022, company); total ~$107m+ before the sale (stylized sum; earlier seed and grant funding not disclosed)
Exit: Acquisition by BioNTech announced 10 January 2023 for up to ~£562m (~$682m, Reuters); completed mid-2023 (31 July 2023 per one report; verify), one secondary report gives ~€500m total consideration including contingent payments, which does not match the company's up to ~£562m (~€630m at the time, stylized) and may be a completion-date fair value (reports differ; the company terms are preferred, verify)
Key partnerships: BioNTech (joint AI lab from November 2020); Google (investor; DeepPCB Pro on Google Cloud); Google DeepMind (research collaborations, reported); Nvidia (H100s for Kyber; earlier Nvidia Inception membership, verify); Deutsche Bahn (multi-year train-planning project); Fraport; Syngenta Seeds (June 2024); Wilo (March 2026); Equinix (hosts Kyber in Saint-Denis)
Signature moves (incl. failures): Founding in Tunis and the London move (2014–15); Series A, DeepPCB and industrial optimisation (2019); the BioNTech lab and the variant early-warning system (2020–22); the $100m Series B (2022); the BioNTech acquisition (2023); the Nucleotide Transformer and open genomics models (2023–25); AI Day, Kyber and Laila (2024); parent retrenchment and the two-business question (2025–26)

8 strategic moves analysed

Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.

2014
Founding in Tunis and the London Move
Founding
2019
Series A DeepPCB and Industrial Optimisation
Funding round / launch
2020
BioNTech AI Lab and the Variant Early Warning System
Partnership / launch
2022
Series B 100m with BioNTech Google and G42
Funding round
2023
BioNTech Acquisition
Acquisition
2023
Nucleotide Transformer and Open Genomics Models
Model release
2024
AI Day Kyber Laila and Bayesian Flow Networks
Launch / compute
2026
Parent Retrenchment and the Two Business Question
Restructuring (at the parent) / partnership

← Previous

Infosys

Intel